Bio-Techne Corporation (NASDAQ: TECH) has recently released its third quarter fiscal 2025 financial results, showing robust growth and strategic execution despite a dynamic macroeconomic environment. This authoritative update focuses on the “who, what, when, and where” of Bio-Techne’s performance, complemented by quantitative insights and contextual understanding from previous earnings commentary.
When: Results for the quarter ended March 31, 2025.
What: Total net sales grew by 4% to $316.2 million; organic revenue, a critical performance metric excluding currency and held-for-sale business impacts, rose 6%.
Who: Protein Sciences and Diagnostics and Spatial Biology are the core business segments driving growth.
Where: Operations globally, with strong pharma end-market improvements especially from large pharmaceutical partners.
Bio-Techne’s GAAP EPS was reported at \(0.14, down from \)0.31 the prior year period. The decline was influenced by a non-recurring arbitration award impacting the operating margin, which stood at 12.2%, down from 22.1% in the previous year. However, adjusted EPS improved to \(0.56 per share (up from \)0.48), demonstrating strong underlying profitability.
Adjusted operating income increased 11% to $110.3 million, with an adjusted operating margin of 34.9%, an improvement of 190 basis points compared to fiscal Q3 2024. This margin growth was driven by volume leverage and enhanced profitability initiatives.
Protein Sciences Segment: One of the world’s leading suppliers of specialized proteins and immunoassays, this segment grew organic revenues 7% to $227.7 million and saw operating margins improve to 45.6% from 44.2% last year. The segment’s strong performance aligns with management’s commentary from previous calls highlighting solid pharma end market conditions and strong commercial execution.
Diagnostics and Spatial Biology Segment: Revenue increased 2% organically to $89.2 million, with a stable operating margin of 9.4%. This segment supports oncology diagnostics and in vitro diagnostic markets, maintaining steady growth despite macroeconomic challenges.
CEO Kim Kelderman emphasized the company’s well-positioned portfolio across geography and markets, supported by an experienced leadership team to navigate the current environment. Bio-Techne’s commitment to scientific advancements and diagnostic solutions underpins its differentiated financial performance.
Income Statement: A mixed quarter with GAAP EPS decline due to non-recurring items but strong adjusted metrics.
Cash Flows: Operating cash flow remains robust at $189.4 million for the nine months ending March 31, 2025, supporting ongoing investments and shareholder returns.
Balance Sheet: Healthy cash and equivalents of \(140.7 million and manageable long-term debt of \)330 million, providing ample liquidity for operational flexibility.
GAAP Gross Margin stood at a strong 67.9% in Q3 FY25, a slight improvement over 67.4% in Q3 FY24.
Adjusted Operating Margin rose to 34.9%, showcasing successful profitability initiatives.
Non-GAAP adjusted net earnings rose to \(88.3 million from \)76.4 million year-over-year.
Bio-Techne demonstrates resilient growth backed by strategic focus in its high-value protein sciences and diagnostics segments, navigating macroeconomic fluctuations while driving shareholder value. The combination of solid organic growth, increased adjusted margins, and steady cash generation confirms the company’s robust operational and financial footing.
For a detailed review, the full 8-K filing is accessible here: Bio-Techne Q3 Fiscal 2025 Report.
This analysis follows up on Bio-Techne’s prior earnings calls where management highlighted improving pharma end markets particularly with large pharma partnerships and ongoing profitability initiatives. These strategic themes continue to materialize in strong segment-level growth and margin expansion.
Tags: Bio-Techne, Fiscal Q3 2025, Protein Sciences, Diagnostics, Financial Performance